Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 8, 2011, Pages 1103-1111

  Samandari, Taraz ^a,b   Bishai, David ^c   Luteijn, Michiel ^d   Mosimaneotsile, Barudi ^a   Motsamai, Oaitse ^e   Postma, Maarten ^f   Hubben, Gijs ^d,e  

^a BOTUSA Gaborone and Francistown   (South Africa)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BaseCase Software   (Germany)

^e Department of HIV AIDS Prevention and Care   (Botswana)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Chest x ray; Cost effectiveness; Human immunodeficiency virus; Isoniazid preventive therapy; Tuberculosis

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BOTSWANA; COST BENEFIT ANALYSIS; DEATH; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SCREENING; THORAX RADIOGRAPHY;

ANTITUBERCULAR AGENTS; BOTSWANA; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEALTH CARE COSTS; HUMANS; ISONIAZID; MASS CHEST X-RAY; MODELS, ECONOMIC; TUBERCULOSIS, PULMONARY;

EID: 79954619598     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201004-0620OC     Document Type: Article

References (53)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC; WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country [consensus statement]. JAMA 1999;282:677-686. (Pubitemid 29384157)
2. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998;47(RR-20):1-58.
3. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000;14:S47-S56.
4. Gaborone Central Statistics Office. Botswana AIDS impact survey, BAIS 2005. Gaborone, Botswana: Gaborone Central Statistics Office; 2005.
5. Botswana National Tuberculosis Control Program. Botswana National Tuberculosis Control Program annual report. Gaborone, Botswana: Epidemiology Section, Ministry of Health, 2002.
6. Gammino VM, Mboya JJ, Samandari T, Sheth A, Almquist J, Nkubito G, Jimbo W, Obita G, Roels TH, Wells CD, et al. Baseline evaluation of routine HIV testing among tuberculosis patients in Botswana. Int J Tuberc Lung Dis 2008;12:92-94.
7. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457. (Pubitemid 28558603)
8. Whalen C, Horsburgh CR Jr, Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997;11:455-460. (Pubitemid 27113006)
9. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a metaanalysis of randomized controlled trials. AIDS 1999;13:501-507.
10. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;1:CD000171.
11. Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS 1999;13:1549-1556. (Pubitemid 29396688)
12. Hausler HP, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, Karpakis B, Godfrey-Faussett P. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 2006;84:528-536.
13. Shrestha RK, Mugisha B, Bunnell R, Mermin J, Hitimana-Lukanika C, Odeke R, Madra P, Adatu F, Blandford JM. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda. Int J Tuberc Lung Dis 2006;10:656-662. (Pubitemid 43845027)
14. Shrestha RK, Mugisha B, Bunnell R, Mermin J, Odeke R, Madra P, Hitimana-Lukanika C, Adatu-Engwau F, Blandford JM. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. Int J Tuberc Lung Dis 2007;11:747-754. (Pubitemid 47056983)
15. World Health Organization. Policy statement on preventive therapy against tuberculosis in people living with HIV-report of a meeting held in Geneva, 18-20 February 1998. WHO/TB/98.255. Geneva, Switzerland: World Health Organization; 1998.
16. Mosimaneotsile B, Talbot EA, Moeti TL, Hone NM, Moalosi G, Moffat HJ, Lee EJ, Kenyon TA. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003;362:1551-1552. (Pubitemid 37410196)
17. Agizew TB, Arwady MA, Yoon JC, Nyirenda S, Mosimaneotsile B, Tedla Z, Motsamai O, Kilmarx PH, Wells CD, Samandari T. Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. Int J Tuberc Lung Dis 2010;14:45-51.
18. TreeAge Software. TreeAge Pro 2009 software. Williamstown, MA: TreeAge Software; 2009.
19. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, Godfrey-Faussett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-222. (Pubitemid 32142297)
20. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-2064. (Pubitemid 34680968)
21. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150-158. (Pubitemid 40096371)
22. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008;22:1859-1867.
23. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance, African region. Geneva, Switzerland: World Health Organization; 2005.
24. Mugisha B, Bock N, Mermin J, Odeke RM, Miller B, tu-Engwau F, Granich R, Bunnell R. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis 2006;10:761-767. (Pubitemid 44031390)
25. World Health Organization. Report of a "lessons learnt" workshop on the six ProTEST pilot projects in Malawi, South Africa and Zambia. 3-6 February 2004. WHO/HTM/TB/2004.336. Geneva, Switzerland: World Health Organization; 2004.
26. Agizew T, Bachhuber MA, Nyirenda S, Makwaruzi VZ, Tedla Z, Tallaksen RJ, Parker JE, Mboya JJ, Samandari T. Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults. Int J Tuberc Lung Dis 2010;14:324-331.
27. Graham S, Das GK, Hidvegi RJ, Hanson R, Kosiuk J, Al ZK, Menzies D. Chest radiograph abnormalities associated with tuberculosis: reproducibility and yield of active cases. Int J Tuberc Lung Dis 2002;6:137-142. (Pubitemid 34263704)
28. World Health Organisation. Toman's tuberculosis case detection, treatment, and monitoring-questions and answers. Geneva, Switzerland: World Health Organization; 2004.
29. Zellweger JP, Heinzer R, Touray M, Vidondo B, Altpeter E. Intraobserver and overall agreement in the radiological assessment of tuberculosis. Int J Tuberc Lung Dis 2006;10:1123-1126. (Pubitemid 44519350)
30. Nelson LJ, Talbot EA, Mwasekaga MJ, Ngirubiu PK, Mwansa RA, Notha M, Wells CD. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005;366:488-490. (Pubitemid 41111698)
31. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew T, Tedla Z, Motsamai O, Kilmarx PH, Wells CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing anti-retroviral therapy: a Botswana experience, 2004-2006. J Acquir Immune Defic Syndr 2010;54:71-77.
32. Botswana Ministry of Health. Botswana National Tuberculosis Program manual for health care workers. Gaborone, Botswana: Ministry of Health; 2007.
33. Botswana National Tuberculosis Control Program. Botswana National Tuberculosis Control Program annual report. Gaborone, Botswana: Epidemiology Section, Ministry of Health, 2005.
34. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001;32:623-632. (Pubitemid 32565005)
35. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007;196:S86-S107. (Pubitemid 47206088)
36. Public Service Management Directive No. 1 of 2008. Adjustment of salary scales and review of allowances. DP 2/5 XI (115) 02/22/2008.
37. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available from www.who.int/choice/en/.
38. Basu S, Maru D, Poolman E, Galvani A. Primary and secondary tuberculosis preventive treatment in HIV clinics: simulating alternative strategies. Int J Tuberc Lung Dis 2009;13:652-658.
39. Anonymous. Isoniazid in pulmonary tuberculosis; report on a trial conducted under the auspices of the Medical Research Council of Ireland. Ir J Med Sci 1953;6:421-432.
40. Fox W, Sutherland I. The clinical significance of positive cultures and of isoniazid-resistant tubercle bacilli during the treatment of pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Thorax 1955;10:85-98.
41. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, Ramachandran K. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964;31:273-294.
42. van Soolingen D, Borgdorff MW, de Haas PE, Sebek MM, Veen J, Dessens M, Kremer K, van Embden JD. Molecular epidemiology of tuberculosis in The Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999;180:726-736. (Pubitemid 29411359)
43. Kenyon TA, Creek T, Laserson K, Makhoa M, Chimidza N, Mwasekaga M, Tappero J, Lockman S, Moeti T, Binkin N. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int J Tuberc Lung Dis 2002;6:843-850. (Pubitemid 35190696)
44. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002;34:543-546. (Pubitemid 34112278)
45. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana. Curr Infect Dis Rep 2008;10:69-73. (Pubitemid 351419364)
46. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-1448. (Pubitemid 46988004)
47. Golub JE, Pronyk P, Mohapy L, Thsabangu N, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-636.
48. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis before isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006;10:523-529. (Pubitemid 43667640)
49. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza KC, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-2147. (Pubitemid 33101821)
50. van Cleeff MR, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR. The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis 2005;5:111.
51. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-2545. (Pubitemid 30324196)
52. Santha T, Garg R, Frieden TR, Chandrasekaran V, Subramani R, Gopi PG, Selvakumar N, Ganapathy S, Charles N, Rajamma J, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002;6:780-788. (Pubitemid 34988048)
53. Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, Wirima JJ, Salaniponi FM, Liomba G, Maher D, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg 1998;92:343-347. (Pubitemid 28286941)